Muscle Spasticity - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Muscle Spasticity - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Muscle Spasticity - Pipeline Review, H1 2015', provides an overview of the Muscle Spasticity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Spasticity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Spasticity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Muscle Spasticity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Muscle Spasticity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Muscle Spasticity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Muscle Spasticity pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Muscle Spasticity
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Muscle Spasticity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Muscle Spasticity Overview 6
Therapeutics Development 7
Pipeline Products for Muscle Spasticity - Overview 7
Pipeline Products for Muscle Spasticity - Comparative Analysis 8
Muscle Spasticity - Therapeutics under Development by Companies 9
Muscle Spasticity - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Muscle Spasticity - Products under Development by Companies 13
Muscle Spasticity - Companies Involved in Therapeutics Development 14
Daewoong Pharmaceutical Co., Ltd. 14
Ipsen S.A. 15
OBI Pharma, Inc. 16
Sanochemia Pharmazeutika AG 17
Sun Pharma Advanced Research Company Ltd. 18
Muscle Spasticity - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
abobotulinumtoxin A - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
baclofen ER - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NB-2221 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
OBI-858 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
onabotulinumtoxin A - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
tolperisone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Muscle Spasticity - Recent Pipeline Updates 36
Muscle Spasticity - Dormant Projects 38
Muscle Spasticity - Discontinued Products 39
Muscle Spasticity - Product Development Milestones 40
Featured News & Press Releases 40
Jan 26, 2015: Ipsen announces topline results of two double-blind phase III studies of Dysport in lower limb spasticity in children and in adults 40
Nov 28, 2014: Ipsen Announces FDA Acceptance of Filing for Dysport in the Treatment of Upper Limb Spasticity in Adult Patients 42
Nov 14, 2014: Ipsen Biopharmaceuticals Presents Dysport (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly 43
Jul 11, 2014: Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe 44
Apr 12, 2014: Ipsen announces a first set of results on positive phase III clinical study of Dysport in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul 45
Dec 17, 2013: Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport in the treatment of Adults suffering from Upper Limb Spasticity 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

List of Tables
Number of Products under Development for Muscle Spasticity, H1 2015 7
Number of Products under Development for Muscle Spasticity - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Muscle Spasticity - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 14
Muscle Spasticity - Pipeline by Ipsen S.A., H1 2015 15
Muscle Spasticity - Pipeline by OBI Pharma, Inc., H1 2015 16
Muscle Spasticity - Pipeline by Sanochemia Pharmazeutika AG, H1 2015 17
Muscle Spasticity - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Muscle Spasticity Therapeutics - Recent Pipeline Updates, H1 2015 36
Muscle Spasticity - Dormant Projects, H1 2015 38
Muscle Spasticity - Discontinued Products, H1 2015 39